According to these results, it can be assumed that VEGFA overexpression in tumor tissues could be considered an emerging biomarker to predict response to second-line treatment with Ramucirumab and PTX and to identify GC patients who will benefit from this therapy. This evidence concerns the gene VEGFA and gastric cancer.